CABAPAN is a cost effective product for the treatment of metastatic castration resistant prostrate cancer
Panacea Biotec has launched indigenously developed high quality oncology product, CABAPAN (Cabazitaxel Injection), for treatment of metastatic Castration Resistant Prostrate Cancer (mCRPC).
CABAPAN has been developed by Panacea Biotec’s state-of-the-art Global Research and Development Center (GRAND), Mumbai and manufactured at modern production facility complying with global current Good Manufacturing Practices (cGMP), at Baddi, Himachal Pradesh. CABAPAN aims to improve accessibility of this treatment for the benefit of patients at an affordable cost as part of our commitment to Government of India’s ‘MAKE IN INDIA’ mission.
EP News Bureau – Mumbai
- Advertisement -
Comments are closed.